U ntil recently, no treatments were available to help slow the progression of metabolic dysfunction–associated steatohepatitis (MASH), a severe form of fatty liver disease. But in March 2024, a ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a more advanced form of metabolic dysfunction-associated steatotic liver disease (MASLD). It happens when fat buildup progresses to ...
Eli Lilly metabolic disorder medication tirzepatide, already approved in type 2 diabetes and weight management, now has early clinical data indicating it can also help patients with a fatty liver ...
Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...
Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. The lack of head-to-head trials complicates treatment prioritization, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results